Pfizer CEO Albert Bourla (AP Images)
April 28, 2022 08:37 AM EDTUpdated 01:23 PM
R&D
Pharma
Cell/Gene Tx

Pfiz­er can restart PhI­II tri­al of Duchenne gene ther­a­py, now on track for late-2023 FDA ap­proval re­quest 

Kyle LaHucik

Senior Reporter

Pfiz­er’s path at get­ting a gene ther­a­py to mar­ket for pa­tients with Duchenne mus­cu­lar dy­s­tro­phy just got a lit­tle clear­er af­ter a hazy 2021 that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times